HK1178088A1 - 種 受體拮抗劑在過敏性接觸性皮膚炎及牛皮癬治療中的使用 - Google Patents

種 受體拮抗劑在過敏性接觸性皮膚炎及牛皮癬治療中的使用

Info

Publication number
HK1178088A1
HK1178088A1 HK13105948.7A HK13105948A HK1178088A1 HK 1178088 A1 HK1178088 A1 HK 1178088A1 HK 13105948 A HK13105948 A HK 13105948A HK 1178088 A1 HK1178088 A1 HK 1178088A1
Authority
HK
Hong Kong
Prior art keywords
psoriasis
treatment
receptor antagonist
contact dermatitis
allergic contact
Prior art date
Application number
HK13105948.7A
Other languages
English (en)
Inventor
Kiyoshi Kanazawa
Kazuhiko Nonomura
Takako Okumura
Shinichi Koizumi
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of HK1178088A1 publication Critical patent/HK1178088A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK13105948.7A 2010-02-22 2013-05-21 種 受體拮抗劑在過敏性接觸性皮膚炎及牛皮癬治療中的使用 HK1178088A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28250610P 2010-02-22 2010-02-22
PCT/JP2011/000994 WO2011102149A1 (en) 2010-02-22 2011-02-22 Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases

Publications (1)

Publication Number Publication Date
HK1178088A1 true HK1178088A1 (zh) 2013-09-06

Family

ID=44482754

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13105948.7A HK1178088A1 (zh) 2010-02-22 2013-05-21 種 受體拮抗劑在過敏性接觸性皮膚炎及牛皮癬治療中的使用
HK18107808.7A HK1249401A1 (zh) 2010-02-22 2018-06-15 Ep-4受體拮抗劑在治療il-23介導疾病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18107808.7A HK1249401A1 (zh) 2010-02-22 2018-06-15 Ep-4受體拮抗劑在治療il-23介導疾病中的用途

Country Status (12)

Country Link
US (1) US9457084B2 (zh)
EP (1) EP2538978B1 (zh)
JP (2) JP6152643B2 (zh)
KR (1) KR101780666B1 (zh)
CN (2) CN107693518A (zh)
BR (1) BR112012020236A2 (zh)
CA (2) CA3009937C (zh)
ES (1) ES2600355T3 (zh)
HK (2) HK1178088A1 (zh)
MX (1) MX341482B (zh)
RU (1) RU2571816C2 (zh)
WO (1) WO2011102149A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
PT3083562T (pt) 2013-12-17 2017-12-13 Lilly Co Eli Derivados de aminas cíclicas de fenoxietilo e a sua atividade como moduladores de recetores ep4
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
PL3113774T3 (pl) 2014-03-06 2022-06-13 Elanco Animal Health Incorporated Kompozycje grapiprantu i sposoby ich zastosowania
CN108473497B (zh) * 2015-10-16 2021-09-10 卫材R&D 管理有限公司 Ep4拮抗剂
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
AU2018210525B2 (en) 2017-01-23 2022-06-02 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
EP3781162A1 (en) 2018-04-16 2021-02-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
AU2019305095A1 (en) 2018-07-20 2020-12-17 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
PL3860998T3 (pl) 2018-10-05 2024-06-17 Annapurna Bio Inc. Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj
MX2021009082A (es) 2019-01-30 2021-09-08 Avista Pharma Solutions Inc Compuestos quimicos.
US11512088B2 (en) 2019-01-30 2022-11-29 Avista Pharma Solutions, Inc. Synthetic process and intermediates
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CA2481535C (en) * 2002-04-12 2010-08-17 Pfizer Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
ATE396182T1 (de) * 2003-01-29 2008-06-15 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
RS20060143A (en) * 2003-09-03 2008-06-05 Pfizer Inc., Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
MXPA06012172A (es) * 2004-04-20 2007-01-17 Pfizer Prod Inc Combinaciones que comprenden ligandos alfa-2-delta y antagonistas del receptor ep4.
KR20070006891A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
DE602006014516D1 (zh) * 2005-03-11 2010-07-08 Raqualia Pharma Inc
EP1886987A1 (en) * 2006-08-11 2008-02-13 Givaudan S.A. Process for producing 2,2,3-trimethylcyclopent-3-enecarbaldehyde (campholytic aldehyde)
WO2008017164A1 (en) * 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands

Also Published As

Publication number Publication date
BR112012020236A2 (pt) 2016-05-17
KR101780666B1 (ko) 2017-09-21
RU2571816C2 (ru) 2015-12-20
JP2017095511A (ja) 2017-06-01
JP6152643B2 (ja) 2017-06-28
CA3009937A1 (en) 2011-08-25
CA3009937C (en) 2020-12-15
CN107693518A (zh) 2018-02-16
EP2538978B1 (en) 2016-09-07
CA2789665A1 (en) 2011-08-25
CA2789665C (en) 2020-06-16
CN102770159A (zh) 2012-11-07
KR20130040787A (ko) 2013-04-24
MX2012009503A (es) 2012-09-12
ES2600355T3 (es) 2017-02-08
WO2011102149A1 (en) 2011-08-25
EP2538978A1 (en) 2013-01-02
JP2013520397A (ja) 2013-06-06
US20120316197A1 (en) 2012-12-13
RU2012140450A (ru) 2014-03-27
MX341482B (es) 2016-08-22
HK1249401A1 (zh) 2018-11-02
US9457084B2 (en) 2016-10-04
EP2538978A4 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
HK1178088A1 (zh) 種 受體拮抗劑在過敏性接觸性皮膚炎及牛皮癬治療中的使用
HRP20171352T1 (hr) Wnt-antagonisti i postupci liječenja
GB2498121B (en) Treatment device and method of use
IL267700A (en) Lidocaine administration regimen for long-term treatment of bladder pain and voiding irritation
EP2637684A4 (en) BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR
EP2611413A4 (en) SKIN COMPOSITIONS AND THEIR APPLICATIONS
EP2624790A4 (en) INTERVERTEBRAL DEVICE AND METHODS OF USE
EP2571421A4 (en) DETECTION DEVICES AND METHODS OF USE THEREOF
AP2013007331A0 (en) TRPM8 antagonists and their use in treatments
EP2603221A4 (en) GGF2 AND METHODS OF USE
IL221043A0 (en) Modified release formulation and methods of use
IL236637A (en) Diploorulctam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditions
IL233875A (en) Preparation and use for the treatment of anal fissures
HK1187366A1 (zh) 新型細菌及所述細菌提取物、以及其在皮膚病中的用途
HK1196943A1 (zh) 作為用於治療酒精依賴和濫用的 受體拮抗劑的螺噻吩並吡喃-呱啶衍生物
EP2861998A4 (en) ACELLULAR DOSING DEVICE AND METHODS OF USE
EP2858670B8 (en) Antagonists of il-17 isoforms and their uses
GB201223374D0 (en) Personal care composition and methods of making the same
GB2483313B (en) Use of probiotic strain GM-080 in treating cardiac inflammation and apoptosis
EP2659303A4 (en) EXTENDABLE GLASSES AND USE METHOD THEREFOR
EP2809309A4 (en) RETINALDEHYDMIMETICS AND INHIBITORS OF RETINALDEHYDE DEHYDROGENASE I FOR THE TREATMENT OF ILLNESSES
IL226134A0 (en) Ophthalmic preparations with buffer and methods for their preparation
AU2010901520A0 (en) Substituted thienobenzodiazepines and their use in the treatment of CNS disorders
EP2525660A4 (en) FORMULATION WITH MODIFIED RELEASE AND USE METHOD

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230220